State of Texas   Report issue

Government Phase 1 Phase 2 Phase 4
Founded: Austin TX United States (1845)

Organization Overview

First Clinical Trial
2012
NCT01310842
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Cancer Prevention Research Institute of Texas

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Blast Crisis (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma, Renal Cell (Phase 1)

Graft vs Host Disease (Phase 2)

Hematologic Diseases (Phase 1)

Leukemia (Phase 2)

Leukemia, Erythroblastic, Acute (Phase 2)

Leukemia, Megakaryoblastic, Acute (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Accelerated Phase (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Leukemia, Myelomonocytic, Chronic (Phase 2)

Leukemia, Myelomonocytic, Juvenile (Phase 2)

Lung Neoplasms (Phase 1)

Lymphoma (Phase 1)

Lymphoma, Mantle-Cell (Phase 1)

Melanoma (Phase 2)

Multiple Myeloma (Phase 1)

Myelodysplastic Syndromes (Phase 2)

Papilloma (Phase 4)

Preleukemia (Phase 2)

Skin Neoplasms (Phase 1)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 18
  • # of Trial APIs: 34